Nantkwest inc stock
WitrynaNantKwest Inc is a United States-based firm functioning in the healthcare sector. It is focused on providing immunotherapeutic agents, especially natural killer cells to treat cancer, infectious and inflammatory diseases. Natural Killer (NK) cells are ancient cells in the human body designed to recognize and detect cells under stress or infected. Witryna31 sty 2024 · On average, NantKwest Inc executives and independent directors trade stock every 33 days with the average trade being worth of $5,362,832. The most recent stock trade was executed by Richard Adcock on 5 February 2024, trading 150,000 units of NK stock currently worth $4,873,500.
Nantkwest inc stock
Did you know?
Witryna8 mar 2024 · NantKwest, Inc. ( NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that its stockholders approved by the … Witryna21 gru 2024 · (RTTNews) - ImmunityBio, a privately-held immunotherapy company, and therapeutics company NantKwest, Inc. (NK) announced Monday that they have …
WitrynaThe NantKwest, Inc. stock price is closed at $ 32.49 with a total market cap valuation of $ 3.55B (44M shares outstanding). The NantKwest, Inc. is trading on NASDAQ with … WitrynaNantKwest is a clinical-stage immunotherapy company focused on harnessing the immune system to treat disease. Acquired by ImmunityBio San Diego, California, United States 51-100 Post-IPO Equity Public www.nantkwest.com 46,504 Highlights Stock Symbol NASDAQ:NK Investments 1 Exits 1 Total Funding Amount $103.5M Contacts …
WitrynaOur investigational IL-15 superagonist, N-803, and NK-92®-engineered cells have demonstrated wide therapeutic potential across multiple tumor types, and, in clinical studies, have proven to be well-tolerated, making them ideal for clinical trial investigations. Learn More Solutions for Research Scientists Witryna6 cze 2024 · * NantKwest Inc - expansion of company's existing nant cancer vaccine program in pancreatic cancer to target a number of additional tumor types * NantKwest - first combination off shelf NK,...
WitrynaNantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and …
WitrynaNantKwest Inc historical valuations - : view the valuation bands based on price-earnings, price-sales and price-book. 🚀 Enjoy a 7-Day Free Trial Thru Apr 06, 2024! Sign Up gullah geechee cultural heritage centerWitrynaNantKwest Inc 1.64 -0.03 -1.80% General Chart News & Analysis Financials Technical Forum Technical Analysis Candlestick Patterns Analyst Price Target IBRX Candlestick Patterns Candlestick Chart... gullah geechee corridor victoria smallsWitryna29 lis 2024 · American Stock Transfer & Trust Company, LLC. AST Shareholder Services Call Center Toll Free: 800.937.5449 Local & International: 718-921-8124 … bowl bound college football avalon hillWitrynaNantKwest Inc quote is equal to 33.900 USD at 2024-04-16. Based on our forecasts, a long-term increase is expected, the "NK" stock price prognosis for 2026-12-16 is 161.891 USD. With a 5-year investment, the revenue is expected to be around +377.55%. Your current $100 investment may be up to $477.55 in 2027. gullah geechee fishingWitrynaNantKwest Inc Registered Shs's market capitalization is $799.29 M by 435.84 M shares outstanding. Is NantKwest stock a Buy, Sell or Hold? NantKwest stock has … gullah geechee festival 2021Witryna10 kwi 2024 · NantKwest, Inc. Recent Mergers and Acquisitions. ... All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday ... gullah geechee corridor jacksonville flWitryna24 lut 2024 · NantKwest Transaction As previously announced on December 21, 2024, ImmunityBio entered into an agreement to combine in a stock-for-stock transaction with NantKwest. The combination, which is expected to close in the first half of 2024, will create a leading immunotherapy and cell therapy company focused on oncology and … gullah geechee cultural heritage commission